ProCE Banner Activity


BRCA Testing and the Role of PARP Inhibition in Early Breast Cancer: A Multidisciplinary Roundtable

Text Module

Gain perspectives from a multidisciplinary panel of experts as they discuss the importance of and challenges with implementing BRCA testing in patients with early breast cancer and the role of adjuvant PARP inhibition.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 27, 2023

Expiration: March 26, 2024

No longer available for credit.



Constance Albarracin

Constance Albarracin, MD, PhD

Director, Breast Fellowship Program
University of Texas MD Anderson Cancer Center
Houston, Texas

Banu Arun

Banu Arun, MD

Professor, Breast Medical Oncology
Co-Director, Clinical Cancer Genetics 
Executive Director, Cancer Genetics
MD Anderson Cancer Networks
University of Texas MD Anderson Cancer Center
Houston, Texas

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky

Emilia Diego

Emilia Diego, MD, FACS

Division Chief
Division of Breast Surgery
University of Pittsburgh Medical Center
Division of Breast Surgery
UPMC Hillman Cancer Center Breast Program
Pittsburgh, Pennsylvania

Charles E. Geyer, Jr.

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Marissa Marti-Smith

Marissa Marti-Smith, APRN, AGNP-C, AOCNP

Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas

Kristen Shannon

Kristen Shannon, MS, CGC

Mass General Cancer Center Genetics Program
Mass General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from


Merck Sharp & Dohme, LLC



ProCE Banner

Target Audience

This activity is intended for medical oncologists, pharmacists, NP/PAs, nurses, genetic counselors, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop genetic testing strategies that incorporate best communication techniques and expert guidance for all patient subgroups with EBC that may benefit from PARP inhibition

  • Identify patients who should be tested for BRCA mutations and communicate to colleagues and patients the rationale and steps for corrective action for those not tested

  • Communicate to colleagues and patients the improvement in overall survival gained by adding PARP inhibition to the adjuvant treatment of patients with germline BRCA mutations

  • Integrate PARP inhibition into treatment plans and sequence strategies for patients that may also be appropriate for other newly approved treatments for EBC

  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, improve patient experience and optimize outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Constance Albarracin, MD, PhD, has no relevant financial relationships to disclose.

Banu Arun, MD: researcher (paid to institution): AstraZeneca.

Allison Butts, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca, BeyondSpring.

Emilia Diego, MD, FACS, has no relevant financial relationships to disclose.

Charles E. Geyer, Jr., MD: researcher: AbbVie, AstraZeneca, Daiichi Sankyo, Roche/Genentech; consultant/advisor/speaker: Exact Sciences, SeaGen.

Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, has no relevant financial relationships to disclose.

Kristen Shannon, MS, CGC, has no relevant financial relationships to disclose.

The planner and content peer reviewers from Clinical Care Options, LLC and ProCE, LLC have no relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 27, 2023, through March 26, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-23-085-H01-P.

Type of Activity:  Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.